There have been continuous advances in the field of glucose monitoring during the last four decades, which have led to the development of highly evolved blood glucose meters, non-invasive glucose monitoring (NGM) devices and continuous glucose monitoring systems (CGMS). Glucose monitoring is an integral part of diabetes management, and the maintenance of physiological blood glucose concentration is the only way for a diabetic to avoid life-threatening diabetic complications. CGMS have led to tremendous improvements in diabetic management, as shown by the significant lowering of glycated hemoglobin (HbA1c) in adults with type I diabetes. Most of the CGMS have been minimally-invasive, although the more recent ones are based on NGM techniques. This manuscript reviews the advances in CGMS for diabetes management along with the future prospects and the challenges involved.
References
[1]
Zhang, P.; Zhang, X.; Brown, J.; Vistisen, D.; Sicree, R.; Shaw, J.; Nichols, G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res. Clin. Pract.？2010, 87, 293–301, doi:10.1016/j.diabres.2010.01.026.
[2]
Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care？2004, 27, 1047–1053, doi:10.2337/diacare.27.5.1047.
[3]
Whiting, D.R.; Guariguata, L.; Weil, C.; Shaw, J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract.？2011, 94, 311–321, doi:10.1016/j.diabres.2011.10.029.
[4]
Guariguata, L.; Whiting, D.R.; Weil, C.; Unwin, N. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. Diabetes Res. Clin. Pract.？2011, 94, 322–332, doi:10.1016/j.diabres.2011.10.040.
[5]
IDF Diabetes Atlas, 5th ed. ed.; 2012.
[6]
Aronson, D. Hyperglycemia and the pathobiology of diabetic complications. In Cardiovascular Diabetology: Clinical, Metabolic and Inflammatory Facets; Fisman, F.X., Tenenbaum, A., Eds.; Karger: Basel, Swizerland, 2008; pp. 1–16.
[7]
Dhar, G.C. Intensive glycemic control implications of the ACCORD, ADVANCE, and VADT trials for family physicians. Can. Fam. Phys.？2009, 55, 803–804.
[8]
Bonds, D.E.; Kurashige, E.M.; Bergenstal, R.; Brillon, D.; Domanski, M.; Felicetta, J.V.; Fonseca, V.A.; Hall, K.; Hramiak, I.; Miller, M.E.; Osei, K.; Simons-Morton, D.G. Severe hypoglycemia monitoring and risk management procedures in the action to control cardiovascular risk in diabetes (ACCORD) trial. Amer. J. Cardiol.？2007, 99, S80–S89, doi:10.1016/j.amjcard.2007.03.026.
[9]
Bonds, D.E.; Miller, M.E.; Bergenstal, R.M.; Buse, J.B.; Byington, R.P.; Cutler, J.A.; Dudl, R.J.; Ismail-Beigi, F.; Kimel, A.R.; Hoogwerf, B.; Horowitz, K.R.; Savage, P.J.; Seaquist, E.R.; Simmons, D.L.; Sivitz, W.I.; Speril-Hillen, J.M.; Sweeney, M.E. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. BMJ？2009, 339, doi:10.1136/bmj.b4909.
[10]
Riddle, M.C.; Ambrosius, W.T.; Brillon, D.J.; Buse, J.B.; Byington, R.P.; Cohen, R.M.; Goff, D.C.; Malozowski, S.; Margolis, K.L.; Probstfield, J.L.; Schnall, A.; Seaquist, E.R. Epidemiologic relationships between A1C and all-course mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care？2010, 33, 983–990.
[11]
Skyler, J.S. The economic burden of diabetes and the benefits of improved glycemic control: The potential role of a continuous glucose monitoring system. Diabetes Technol. Ther.？2000, 2, doi:10.1089/15209150050214069.
[12]
Tessier, F.J. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol. Biol.？2010, 58, 214–219, doi:10.1016/j.patbio.2009.09.014.
[13]
Vashist, S.K.; Al-Rubeaan, K. Rapidly growing importance of glycated haemoglobin (HbA1c) in diabetic management. J. Basic Appl. Sci.？2013, 9, 337–340.
[14]
Forbes, J.M.; Soldatos, G.; Thomas, M.C. Below the radar: Advanced glycation end products that detour “around the side”. Clin. Biochem. Rev.？2005, 26, 123–134.
[15]
Monnier, V.M.; Bautista, O.; Kenny, D.; Sell, D.R.; Fogarty, J.; Dahms, W.; Cleary, P.A.; Lachin, J.; Genuth, S. DCCT Skin Collagen Ancillary Study Group. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes. Diabetes？1999, 48, 870–880, doi:10.2337/diabetes.48.4.870.
[16]
Kilhove, B.K.; Giardino, I.; Torjesen, P.A.; Birkeland, K.I.; Berg, T.J.; Thornalley, P.J.; Brownlee, M.; Hanssen, K.F. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism？2003, 52, 163–167, doi:10.1053/meta.2003.50035.
[17]
Schleicher, E.D.; Wagner, E.; Nerlich, A.G. Increased accumulation of the glyoxidation product N？-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest.？1997, 99, 457–468, doi:10.1172/JCI119180.
[18]
Tsukushi, S.; Katsuzaki, T.; Aoyama, I.; Takayama, F.; Miyazaki, T.; Shimokata, K.; Niwa, T. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: Role of the polyol pathway. Kidney Int.？1999, 55, 1970–1976, doi:10.1046/j.1523-1755.1999.00418.x.
[19]
Sugimoto, K.; Nishizawa, Y.; Horiuchi, S.; Yagihashi, S. Localization in human diabetic peripheral nerve of N？-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia？1997, 40, 1380–1387, doi:10.1007/s001250050839.
[20]
Jakus, V.; Rietbrock, N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol. Res.？2004, 53, 131–142.
[21]
Monnier, V.M.; Sell, D.R.; Genuth, S. Glycation products as markers and predictors of the progression of diabetic complications. Ann. N.Y. Acad. Sci.？2005, 1043, 567–581.
[22]
Nass, N.; Bartling, B.; Santos, A.N.; Scheubel, R.J.; B？rgermann, J.; Silber, R.E.; Simm, A. Advanced glycation end products, diabetes and ageing. Z. Gerontol. Geriatrie？2007, 40, 349–356, doi:10.1007/s00391-007-0484-9.
[23]
Wautier, J.L.; Guillausseau, P.J. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab.？2001, 27, 535–542.
[24]
Shimoike, T.; Inoguchi, T.; Umeda, F.; Nawata, H.; Kawano, K.; Ochi, H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism？2000, 49, 1030–1035, doi:10.1053/meta.2000.7738.
Hartog, J.W.L.; Voors, A.A.; Bakker, S.J.L.; Smit, A.J.; van Veldhuisen, D.J. Advanced glycation end-products (AGEs) and heart failure: Pathophysiology and clinical implications. Eur. J. Heart Fail.？2007, 9, 1146–1155, doi:10.1016/j.ejheart.2007.09.009.
[27]
Vlassara, H.; Palace, M.R. Diabetes and advanced glycation endproducts. J. Intern. Med.？2002, 251, 87–101, doi:10.1046/j.1365-2796.2002.00932.x.
[28]
Meerwaldt, R.; Links, T.; Zeebregts, C.; Tio, R.; Hillebrands, L.; Smit, A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc. Diabetol.？2008, 7, doi:10.1186/1475-2840-7-27-29.
[29]
McCarter, R.J.; Hempe, J.M.; Gomez, R.; Chalew, S.A. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care？2004, 27, 1259–1264, doi:10.2337/diacare.27.6.1259.
[30]
Salardi, S.; Zucchini, S.; Santoni, R.; Ragni, L.; Gualandi, S.; Cicognani, A.; Cacciari, E. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA1c in pediatric type 1 diabetic patients. Diabetes Care？2002, 25, 1840–1844, doi:10.2337/diacare.25.10.1840.
[31]
American Diabetes Association. Standards of medical care in diabetes 2008. Diabetes Care？2008, 31, S12–S54, doi:10.2337/dc08-S012.
[32]
Currie, C.J.; Peters, J.R.; Tynan, A.; Evans, M.; Heine, R.J.; Bracco, O.L.; Zagar, T.; Poole, C.D. Survival as a function of HbA1c in people with type 2 diabetes: A retrospective cohort study. Lancet？2010, 375, 481–489, doi:10.1016/S0140-6736(09)61969-3.
[33]
Raghbar, S. The discovery of glycated hemoglobin. Ann. N.Y. Acad. Sci.？2005, 1043, 9–19, doi:10.1196/annals.1333.002.
[34]
Vashist, S.K.; Zheng, D.; Al-Rubeaan, K.; Luong, J.H.; Sheu, FS. Technology behind commercial devices for blood glucose monitoring in diabetes management: A review. Anal. Chim. Acta？2011, 703, 124–136, doi:10.1016/j.aca.2011.07.024.
[35]
Biosensors in Medical Dignostics—Global Strategic Business Report. Available online: http://www.researchandmarkets.com/reports/338842/biosensors_in_medical_diagnostics_global (accessed on 18 October 2013).
[36]
Vashist, S.K. Non-invasive glucose monitoring technology in diabetes management: A review. Anal. Chim. Acta？2012, 750, 16–27, doi:10.1016/j.aca.2012.03.043.
[37]
Bode, B.W.; Schwartz, S.; Stubbs, H.A.; Block, J.E. Glycemic characteristics in continuouslymonitored patients with type 1 and type 2 diabetes: Normative values. Diabetes Care？2005, 28, 2361–2366, doi:10.2337/diacare.28.10.2361.
[38]
Bode, B.; Silver, M.; Weiss, R.; Martin, K. Evaluation of a continuous glucose monitoring system for home-use conditions. Manag. Care？2008, 17, 40–45.
[39]
Vazeou, A. Continuous glucose monitoring in diabetes treatment. Diabetes Res. Clin. Pract.？2011, 93, S125–S130, doi:10.1016/S0168-8227(11)70028-6.
[40]
Girardin, C.M.; Huot, C.; Gonthier, M.; Delvin, E. Continuous glucose monitoring: A review of biochemical perspectives and clinical use in type 1 diabetes. Clin. Biochem.？2009, 42, 136–142, doi:10.1016/j.clinbiochem.2008.09.112.
Klonoff, D.C. A review of continuous glucose monitoring technology. Diabetes Technol. Ther.？2005, 7, 770–775, doi:10.1089/dia.2005.7.770.
[43]
Sola-Gazagnes, A.; Vigeral, C. Emergent technologies applied to diabetes: What do we need to integrate continuous glucose monitoring into daily practice? Diabetes Metab.？2011, 37, S65–S70, doi:10.1016/S1262-3636(11)70968-5.
[44]
Hovorka, R. Continuous glucose monitoring and closed-loop systems. Diabetic Med.？2005, 23, 1–12, doi:10.1111/j.1464-5491.2005.01672.x.
[45]
Hanaire, H. Continuous glucose monitoring and external insulin pump: Towards a subcutaneous closed loop. Diabetes Metab.？2006, 32, 534–538, doi:10.1016/S1262-3636(06)72808-7.
Petrovski, G.; Dimitrovski, C.; Milenkovic, T. Clinical performance of continuous glucose monitoring system in type 1 diabetics. Diabeto. Croat.？2004, 33, 125–129.
[48]
Deiss, D.; Bolinder, J.; Riveline, J.P.; Battelino, T.; Bosi, E.; Tubiana-Rufi, N.; Kerr, D.; Phillip, M. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care？2006, 29, 2730–2732, doi:10.2337/dc06-1134.
[49]
Allen, N.A.; Fain, J.A.; Braun, B.; Chipkin, S.R. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial. Diabetes Res. Clin. Pract.？2008, 80, 371–379, doi:10.1016/j.diabres.2008.01.006.
[50]
Bode, B.W.; Gross, T.M.; Thornton, K.R.; Mastrototaro, J.J. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: A pilot study. Diabetes Res. Clin. Pract.？1999, 46, 183–190, doi:10.1016/S0168-8227(99)00113-8.
[51]
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.？1993, 329, 977–986, doi:10.1056/NEJM199309303291401.
[52]
Guillod, L.; Comte-Perret, S.; Monbaron, D.; Gaillard, R.C.; Ruiz, J. Nocturnal hypoglycemias in type 1 diabetic patients: What we can learn with continuous glucose monitoring? Diabetes Metab.？2007, 33, 360–365, doi:10.1016/j.diabet.2007.03.007.
[53]
Maia, F.F.R.; Araujo, L.R. Effect of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res. Clin. Pract.？2007, 75, 30–34, doi:10.1016/j.diabres.2006.05.009.
[54]
Kaufman, F.R.; Gibson, L.C.; Halvorson, M.; Carpenter, S.; Fisher, L.K.; Pitukcheewanont, P. A pilot study of the continuous glucose monitoring system. Diabetes Care？2001, 24, 2030–2034, doi:10.2337/diacare.24.12.2030.
[55]
Monnier, L.; Colette, C.; Boegner, C.; Pham, T.C.; Lapinski, H.; Boniface, H. Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom? Diabetes Metab.？2007, 33, 247–252, doi:10.1016/j.diabet.2006.11.007.
[56]
Li, G. Evaluation of Contunuous Glucose Monitoring Systems. MSc Thesis, MIT, Cambridge, MA, USA, 2008.
[57]
Garg, S.K.; Smith, J.; Beatson, C.; Lopez-Baca, B.; Voelmle, M.; Gottlieb, P.A. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol. Ther.？2009, 11, 65–72, doi:10.1089/dia.2008.0109.
[58]
Christiansen, M.; Bailey, T.; Watkins, E.; Liljenquist, D.; Price, D.; Nakamura, K.; Boock, R.; Peyser, T. A new-generation continuous glucose monitoring system: Improved accuracy and reliability compared with a pevious-generation system. Diabetes Technol. Ther.？2013, 10, doi:10.1089/dia.2013.0077.
[59]
Piper, H.G.; Alexander, J.L.; Shukla, A.; Pigula, F.; Costello, J.M.; Laussen, P.C.; Jaksic, T.; Agus, M.S.D. Real-time continuous glucose monitoring in pediatric patients during and after cardiac surgery. Pediatrics？2006, 118, 1176–1184, doi:10.1542/peds.2006-0347.
[60]
Geoffrey, M.; Brazg, R.; Richard, W. FreeStyle navigator continuous glucose monitoring system with TRUstart algorithm, a 1-hour warm-up time. J. Diabetes Sci. Technol.？2011, 5, 99–106.
Keenan, B.; Cartaya, R.; Mastrototaro, J. Accuracy of a new real-time continuous glucose monitoring algorithm. J. Diabetes Sci. Technol.？2010, 4, 111–118.
[63]
Harman-Boehm, I.; Gal, A.; Raykhman, A.M.; Zahn, J.D.; Naidis, E.; Mayzel, Y. Noninvasive glucose monitoring: a novel approach. J. Diabetes Sci. Technol.？2009, 3, 253–260.
[64]
Chuang, H.; Trieu, M.Q.; Hurley, J.; Taylor, E.J.; England, M.R.; Nasraway, S.A. Pilot studies of transdermal continuous glucose measurement in outpatient diabetic patients and in patients during and after cardiac surgery. J. Diabetes Sci. Technol.？2008, 2, 595–602.
[65]
The Dexcom？ SEVEN？ Plus. Available online: http://www.dexcom.com/seven-plus (accessed on 18 October 2013).
[66]
Garg, S.K.; Voelmle, M.K.; Beatson, C.R.; Miller, H.A.; Crew, L.B.; Freson, B.J.; Hazenfield, R.M. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy. Diabetes Care？2011, 34, 574–579, doi:10.2337/dc10-1852.
[67]
The Dexcom？ G4 PLATINUM. Available online: http://www.dexcom.com/dexcom-g4-platinum (accessed on 18 October 2013).
[68]
The Guardian？ REAL-Time CGM System. Available online: http://www.medtronicdiabetes.com/products/guardiancgm (accessed on 18 October 2013).
[69]
Mastrototaro, J.; Shin, J.; Marcus, A.; Sulur, G. The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes. J. Diabetes Sci. Technol.？2008, 1, 400–404.
[70]
Tubiana-Rufi, N.; Riveline, J.P.; Dardari, D. Real-time continuous glucose monitoring using Guardian？ RT: From research to clinical practice. Diabetes Metab.？2007, 33, 415–420, doi:10.1016/j.diabet.2007.05.003.
[71]
Bode, B.; Gross, K.; Rikalo, N.; Schwartz, S.; Wahl, T.; Page, C.; Gross, T.; Mastrototaro, J. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: The Guardian continuous monitoring system. Diabetes Technol. Ther.？2004, 6, 105–113, doi:10.1089/152091504773731285.
[72]
Jacobs, B.; Phan, K.; Bertheau, L.; Dogbey, G.; Schwartz, F.; Shubrook, J. Continuous glucose monitoring system in a rural intensive care unit: A pilot study evaluating accuracy and acceptance. J. Diabetes Sci. Technol.？2010, 4, 636–644.
[73]
Mastrototaro, J.; Lee, S. The integrated MiniMed Paradigm Real-Time insulin pump and glucose monitoring system: Implications for improved patient outcomes. Diabetes Technol. Ther.？2009, 11, S37–S43.
[74]
Abbott Diabetes Care. Available online: http://www.abbottdiabetescare.co.uk/your-products/freestyle-navigator (accessed on 18 October 2013).
[75]
Abbott Diabetes Care Deutschland. Available online: https://www.abbott-diabetes-care.de/de-de/ produkte/kontinuierliches-glukose-messsystem/freestyle-navigator-ii/ (accessed on 18 October 2013).
[76]
Lipson, J.; Bernhardt, J.; Block, U.; Freeman, W.R.; Hofmeister, R.; Hristakeva, M.; Lenosky, T.; McNamara, R.; Petrasek, D.; Veltkamp, D.; Waydo, S. Requirements for calibration in noninvasive glucose monitoring by Raman spectroscopy. J. Diabetes Sci. Technol.？2009, 3, 233–241.
[77]
iHealth announces new products. Available online: http://www.ihealthlabs.com/ihealth_news_detail_iHealth-Announces-New-Products_225.htm (accessed on 18 September 2013).
[78]
Freger, D.; Gal, A.; Raykhman, A.M. Method of monitoring glucose level. US patent application US 6954662 B2.
[79]
Kovatchev, B.P.; Gonder-Frederick, L.A.; Cox, D.J.; Clarke, W.L. Evaluating the accuracy of continuous glucose-monitoring sensors: Continuous glucose-error grid analysis illustrated by TheraSense Freestyle Navigator data. Diabetes Care？2004, 27, 1922–1928, doi:10.2337/diacare.27.8.1922.
[80]
Clarke, W.L.; Anderson, S.; Farhy, L.; Breton, M.; Gonder-Frederick, L.; Cox, D.; Kovatchev, B. Evaluating the clinical accuracy of two continuous glucose sensors using continuous glucose error-grid analysis. Diabetes Care？2005, 28, 2412–2417, doi:10.2337/diacare.28.10.2412.
[81]
Klonoff, D.C. Continuous glucose monitoring: Roadmap for 21st century diabetes therapy. Diabetes Care？2005, 28, 1231–1239, doi:10.2337/diacare.28.5.1231.
[82]
Wilson, G.S.; Zhang, Y. Introduction to the glucose sensing problem. In In Vivo Glucose Sensing; Cunningham, D.D., Stenken, J.A., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2009. doi:10.1002/9780470567319.ch1.
[83]
Guerci, B.; Floriot, M.; Bohme, P.; Durain, D.; Benichou, M.; Jellimann, S.; Drouin, P. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care？2003, 26, 582–589, doi:10.2337/diacare.26.3.582.
[84]
Barman, I.; Kong, C.R.; Singh, G.P.; Dasari, R.R.; Feld, M.S. Accurate spectroscopic calibration for noninvasive glucose monitoring by modeling the physiological glucose dynamics. Anal. Chem.？2010, 82, 6104–6114, doi:10.1021/ac100810e.
[85]
Noninvasive glucose monitor closer to market. Available online: http://blogs.umsl.edu/news/2011/03/29/glucose/ (accessed on 18 September 2013).
[86]
Shining a light—literally—on diabetes. Available online: http://web.mit.edu/newsoffice/2010/glucose-monitor-0809.html (accessed on 18 September 2013).
[87]
Klonoff, D.C. Buckingham, B.; Chrisriansen, J.S.; Montori, V.M.; Tamborlane, W.V.; Vigersky, R.A.; Wolpert, H. Continuous glucose monitoring: An endocrine society clinical practice guideline. J. Clin. Endocr. Metab.？2011, 96, 2968–2979, doi:10.1210/jc.2010-2756.
[88]
Edelman, S.V.; Bailey, T.S. Continuous glucose monitoring health outcomes. Diabetes Technol. Ther.？2009, 11, S68–S74.
[89]
Moreno-Fernandez, J.; Gomez, F.J.; Gazquez, M.; Pedroche, M.; Garcia-Manzanares, A.; Tenias, J.M.; Benito, P.; Gomez, I.R. Real-time continuous glucose monitoring or continuous subcutaneous insulin infusion, what goes first?: Results of a pilot study. Diabetes Technol. Ther.？2013, 15, 596–600, doi:10.1089/dia.2013.0033.
[90]
Kestila, K.K.; Ekblad, U.U.; Ronnemaa, T. Continuous glucose monitoring versus self-monitoring of blood glucose in the treatment of gestational diabetes mellitus. Diabetes Res. Clin. Pract.？2007, 77, 174–179, doi:10.1016/j.diabres.2006.12.012.
[91]
Gerard, R. Continuous glucose monitoring and diabetes health outcomes: A critical appraisal. Diabetes Technol. Ther.？2008, 10, 69–80, doi:10.1089/dia.2007.0261.
[92]
Candian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diabetes？2008, 32, S1–S201.
[93]
Halvorson, M.; Carpenter, S.; Kaiserman, K.; Kaufman, F.R. A pilot trial in pediatrics with the sensor-augmented pump: Combining real-time continuous glucose monitoring with the insulin pump. J. Pediatr.？2007, 150, 103–105, doi:10.1016/j.jpeds.2006.08.069.
[94]
Buse, J.B.; Dailey, G.; Ahmann, A.A.; Bergenstal, R.M.; Green, J.B.; Peoples, T.; Tanenberg, R.J.; Yang, Q. Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: The SYTAR 3 experience. Diabetes Technol. Ther.？2011, 13, 601–606, doi:10.1089/dia.2010.0225.
[95]
Norgaard, K.; Scaramuzza, A.; Bratina, N.; Lalic, N.M.; Jarosz-Chobot, P.; Kocsis, G.; Jasinskiene, E.; De Block, C.; Carrette, O.; Castaneda, J.; Cohen, O. Routine senso-augmented pump therapy in type 1 diabetes: The INTERPRET study. Diabetes Technol. Ther.？2013, 15, 273–280, doi:10.1089/dia.2012.0288.
[96]
Schmidt, S.; Norgaard, K. Sensor-sugmented pump therapy at 36 months. Diabetes Technol. Ther.？2012, 14, 1174–1177, doi:10.1089/dia.2012.0148.
[97]
Slover, R.H.; Welsh, J.B.; Criego, A.; Weinzimer, S.A.; Willi, S.M.; Wood, M.A.; Tamborlane, W.V. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr. Diabetes？2012, 13, 6–11, doi:10.1111/j.1399-5448.2011.00793.x.
[98]
Frontino, G.; Bonfanti, R.; Scaramuzza, A.; Rabbone, I.; Meschi, F.; Rigamonti, A.; Battaglino, R.; Favalli, V.; Bonura, C.; Sicignano, S.; Gioia, E.; Zuccotti, G.N.; Cerutti, F.; Chiumello, G. Sensor-augmented pump therapy in very young children with type 1 diabetes: An efficacy and feasibility observational study. Diabetes Technol. Ther.？2012, 14, 762–764, doi:10.1089/dia.2012.0044.
[99]
Hermanides, J.; Engstrom, A.E.; Wentholt, I.M.E.; Sjauw, K.D.; Hoekstra, J.B.L.; Henriques, J.P.S.; de Vries, J.H. Sensor-augmented insulin pump therapy to treat hypoglycemia at the coronary care unit: A randomized clinical pilot trial. Diabetes Technol. Ther.？2010, 12, 537–542, doi:10.1089/dia.2010.0023.
[100]
JDRF CGM Study Group. JRDF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: Research design and methods. Diabetes Technol. Ther.？2008, 10, 310–321, doi:10.1089/dia.2007.0302.
[101]
Routen, A.C. The utility of continuous glucose monitoring in exercise and health science. J. Phys. Educ. Sport？2010, 27, 21–26.
[102]
McLachlan, K.; Jenkins, A.; O’Neal, D. The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy. Aust. N. Z. J. Obstet. Gynaecol.？2007, 47, 186–190, doi:10.1111/j.1479-828X.2007.00716.x.
[103]
Bondia, J.; Tarin, C.; Garcia-Gabin, W.; Esteve, E.; Fernandez-Real, J.M.; Ricart, W.; Vehi, J. Using support vector machines to detect therapeutically incorrect measurements by the MiniMed CGMS？. J. Diabetes Sci. Technol.？2008, 2, 622–629.
[104]
Davis, S.; Alonso, M.D. Hypoglycemia as a barrier to glycemic control. J. Diabetes Complications？2004, 18, 60–68, doi:10.1016/S1056-8727(03)00058-8.
[105]
Hammond, P. Continuous glucose monitoring: The clinical picture. How to interpret and use the data. Pract. Diabetes？2012, 29, 364–368, doi:10.1002/pdi.1723.
[106]
Bartelme, A.; Bridger, P. The role of reimbursement in the adoption of continuous glucose monitors. J. Diabetes Sci. Technol.？2009, 3, 992–995.
[107]
Yates, K.; Milton, A.H.; Dear, K.; Ambler, G. Continuous glucose monitoring-guided insulin adjustment in children and adolescents on near-physiological insulin regimens. Diabetes Care？2006, 29, 1512–1517, doi:10.2337/dc05-2315.
[108]
Golicki, D.T.; Golicka, D.; Groele, L.; Pankowska, E. Continuous glucose monitoring in children with type 1 diabetes mellitus: A systematic review and meta-analysis. Diabetologia？2008, 51, 233–240, doi:10.1007/s00125-007-0884-9.
[109]
Melki, V.; Ayon, F.; Fernandez, M.; Hanaire-Broutin, H. Value and limitations of the continuous glucose monitoring system in the management of type 1 diabetes. Diabetes MeTable？2006, 32, 123–129, doi:10.1016/S1262-3636(07)70258-6.
[110]
Chetty, V.T.; Almulla, A.; Odueyungbo, A.; Thabane, L. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in type 1 diabetic patients: A systematic review. Diabetes Res. Clin. Pract.？2008, 81, 79–87, doi:10.1016/j.diabres.2008.02.014.
[111]
Larson, N.S.; Pinsker, J.E. The role of continuous glucose monitoring in the care of children with type 1 diabetes. Int. J. Pediatr. Endocr.？2013, 8, doi:10.1186/1687-9856-2013-8.
Zheng, D.; Vashist, S.K.; Al-Rubeaan, K.; Lam, E.; Hrapovic, S.; Luong, J.H.T.; Sheu, F.S. Effect of 3-aminopropyltriethoxysilane on the electrocatalysis of carbon nanotubes for reagentless glucose biosensing. JND？2013, 1, 64–73.
[117]
GluCoMo. Available online: http://glucomo.com/site/en/ (accessed on 18 October 2013).
[118]
Gunst, J.; van den Berghe, G. Blood glucose control in the intensive care unit: Benefits and risks. Semin. Dialysis？2010, 23, 157–162, doi:10.1111/j.1525-139X.2010.00702.x.
[119]
Mesotten, D.; van den Berghe, G. Clinical benefits of tight glycaemic control: Focus on the intensive care unit. Best Pract. Res.？2009, 23, 421–429, doi:10.1016/j.bpa.2009.08.006.
[120]
Inoue, S.; Egi, M.; Morita, K. Accuracy of blood-glucose measurements using glucose meters and arterial blood gas analyzers in critically ill adult patients: Systematic review. Crit. Care？2013, 17, doi:10.1186/cc12567.
